CD30+ lymphoma
Conditions
Interventions
case series:none
Sponsors
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin; 2. Patient/legal guardian must be able to read, understand, and sign the Informed Consent Form (ICF); 3. CD30+ lymphoma by INV (any CD30 expression).
Exclusion criteria
Exclusion criteria: 1. Patient who currently participates in or with plan to participate in any interventional clinical trial; 2. Any other reason that, in the investigator's opinion, makes the patient unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serious adverse events (SAEs); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events (AEs);Adverse drug reactions (ADRs);Dose adjustment;Characteristics of patients receiving brentuximab vedotin;Use of brentuximab vedotin;Number of brentuximab vedotin cycles administered;Disease characteristics;Time to next treatment (TTNT );Overall response rate (ORR);Duration of response (DOR) in patients who obtain the complete response;Progression-free survival (PFS) rate (1st year, 2nd year);Overall survival (OS) rate (1st year, 2nd year);Quality of life (QoL);Health economics (cost-effectiveness ratio, C/E); | — |
Countries
China
Contacts
Public ContactZhao Weili
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Outcome results
None listed